Causes, treatment, and AI detection of brain bleeds in children

A brain bleed in children now sits inside a more demanding clinical frame than it did a year ago. In 2026, the AHA/ASA issued its first pediatric stroke recommendations for patients from 28 days through 18 years, including pediatric eligibility considerations for IV alteplase and mechanical thrombectomy in acute ischemic stroke; in late 2025, the International Pediatric Stroke Organization published a dedicated 21-statement consensus for pediatric intracerebral hemorrhage covering prehospital care, imaging protocols, neurocritical care, neurosurgery, and neurointervention thresholds.[1][2][3]

That matters for any discussion of causes, treatment, or AI detection. The question is no longer whether a child’s CT can be scanned by an algorithm that is generally good at finding blood. The question is whether that output fits a pediatric pathway in which age, vascular imaging, anatomy, and the next handoff all matter.

What makes pediatric brain bleeding clinically different

In children, the phrase “brain bleed” can hide a narrower clinical problem: pediatric intracranial hemorrhage is uncommon, heterogeneous, and not well served by simply borrowing adult stroke assumptions. A 2022 review reported pediatric intracerebral hemorrhage incidence at roughly 10–20 per million children per year, with vascular malformations accounting for about 43% of cases and hematologic causes about 28% in a sample of 7,931 children.[4]

Those numbers are enough to explain why the diagnostic pathway cannot be generic. A child with hemorrhage may need urgent recognition of the bleed, but the clinically decisive question often becomes why the bleed occurred and whether a vascular lesion, hematologic disorder, neurosurgical problem, or neurocritical care issue changes what happens next. Treatment is therefore not one intervention. It can involve stabilization, intensive care, hematologic correction, neurosurgical decision-making, and neurointerventional evaluation, depending on the child and the cause.

The AHA/ASA 2026 document is important because it formally brings children into a stroke guideline structure, but its pediatric sections focus primarily on ischemic stroke rather than hemorrhagic stroke.[1][2] For pediatric ICH, the more directly relevant new framework is the IPSO consensus, which concentrates on hemorrhagic stroke management itself.[3]

The imaging requirement AI has to meet

IPSO’s most consequential diagnostic expectation is not merely “image the child quickly.” Statement 6 calls for urgent vascular imaging at the time of ICH diagnosis.[3] That is a higher bar than detecting hyperdensity on a noncontrast CT. It means the first imaging interpretation is part of a chain that may need to identify hemorrhage, trigger vascular imaging, and move the case toward the right pediatric stroke, neurosurgical, neurocritical care, or neurointerventional team.

This is where AI detection tools become interesting, but also where the evidence has to be read tightly. A high negative predictive value may be valuable in a rare condition, and a sensitive detector could help reduce missed hemorrhage on CT. But if the model’s output increases false alarms from pediatric anatomy or artifacts, the consequence is not just a number in a validation table. It is a radiologist, neurologist, emergency team, or neurointerventional service inheriting a flagged case while a child’s vascular imaging and disposition decisions are being made.

What the 2026 AI studies actually show

The strongest pediatric CT evidence currently comes from two retrospective studies published in 2026. Cavallo et al. evaluated an adult-trained AI tool across 21 sites using 1,996 pediatric head CTs and reported 94.2% sensitivity, 94.7% specificity, and 99.4% negative predictive value for intracranial hemorrhage detection.[5] A separate Aidoc BriefCase evaluation in 2,502 pediatric patients reported 96.0% sensitivity and 93.7% specificity.[6]

Those are encouraging numbers, especially for a rare and time-sensitive diagnosis. They also have to be attached to the studied population: both evaluations were limited to children aged 6–17 years.[5][6] They do not validate AI detection in infants, toddlers, preschool-aged children, or the youngest school-aged children. In a pediatric pathway, that is not a small footnote. It excludes a developmentally and anatomically important part of the population that the clinical framework still has to serve.

The Cavallo study is particularly useful because it reports what went wrong. False positives were commonly attributed to streak artifact, at 21.6%, and misclassified normal anatomy, at 18.6%.[5] These are exactly the types of errors that matter in pediatric CT interpretation. A detector that mistakes normal pediatric structures or artifact for blood may still look respectable in aggregate performance metrics, but it can become noisy at the point where the pathway asks clinicians to decide whether urgent vascular imaging, subspecialty review, or transfer should accelerate.

The known pediatric failure modes are not abstract: choroid plexus calcifications and hyperdense venous sinuses can drive false positives, while thin subdural hemorrhages may be missed. The research base provided so far does not show that adult-trained systems have been adequately exposed to these pediatric patterns through dedicated training data, nor does it show prospective performance when the algorithm is embedded in a live pediatric stroke workflow.

Why retrospective sensitivity is not pediatric validation

A retrospective CT study can answer whether a model identified hemorrhage in a curated set of prior cases. It cannot, by itself, answer whether the alert improves the time, accuracy, or safety of the pediatric ICH pathway. It does not show how often clinicians accept or override the alert, whether vascular imaging is ordered sooner, whether transfer decisions change, or whether false positives increase downstream workload in a way that matters.

That distinction is especially important now that IPSO has standardized what the pathway should contain. If urgent vascular imaging is expected at diagnosis, then AI evidence should eventually be judged against that clinical sequence, not only against pixel-level or scan-level hemorrhage detection. The relevant questions become operational: Was the child’s age represented? Was the CT acquisition comparable? Did the model distinguish hemorrhage from normal pediatric anatomy? Did the alert reach the person responsible for the next decision? Did it create avoidable false activation?

The AHA/ASA and IPSO documents also make it harder to overstate the role of AI. They establish a clinical backbone for pediatric stroke care, but neither turns hemorrhage detection into a standalone endpoint. Pediatric ICH management still depends on cause, vascular evaluation, neurocritical status, neurosurgical assessment, and institutional capability.[3] An AI flag may support the first recognition step; it does not replace the pathway that follows.

Where the evidence lands in 2026

For pediatric brain bleeds, the causes and treatment pathway are now better framed than the AI evidence used to support early detection. The clinical standards point toward rapid recognition, immediate etiologic thinking, and urgent vascular imaging at ICH diagnosis. The AI studies point toward potentially useful CT triage performance in children aged 6–17, with sensitivity in the mid-90% range and high reported negative predictive value in one multicenter study.[5][6]

That is an alignment signal, not deployment-grade pediatric proof. Current AI tools appear directionally consistent with the need for rapid imaging interpretation in pediatric ICH care, but they fall short of the evidence standard implied by the new pediatric frameworks. The missing evidence is specific: prospective pediatric trials, dedicated pediatric training data, inclusion of children under 6, and evaluation of pediatric failure modes such as choroid plexus calcifications, hyperdense venous sinuses, and thin subdural hemorrhage.

References

1. 2026 Guideline for the Primary Prevention, Acute Treatment, and Secondary Prevention of Ischemic Stroke, Stroke, January 2026.
2. New guideline expands stroke treatment for adults, offers first pediatric stroke guidance, American Heart Association Newsroom.
3. Consensus Recommendations for the Management of Pediatric Intracerebral Hemorrhage From the International Pediatric Stroke Organization Hemorrhagic Stroke Working Group, Journal of the American Heart Association, December 2025.
4. Pediatric Intracerebral Hemorrhage, Diagnostics, 2022.
5. Adult-Trained Artificial Intelligence for Intracranial Hemorrhage Detection on Pediatric Head CT, PubMed, 2026.
6. Evaluation of Aidoc BriefCase for Intracranial Hemorrhage Detection in Pediatric Head CT, PubMed, 2026.